Enanta Pharmaceuticals, Inc. entered into an Open Market Sale Agreement with Jefferies LLC to sell up to $75,000,000 in common stock through an at-the-market offering. The company will pay Jefferies LLC a commission of up to 3.0% of the gross sales price per share. Enanta Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing small molecule drugs.

The Federal Circuit affirmed a summary judgment decision ruling that the claims of U.S. Patent No. 11,358,953 are invalid, impacting Enanta Pharmaceuticals' lawsuit against Pfizer Inc. regarding Paxlovid infringement. Enanta Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing small molecule drugs.

Enanta Pharmaceuticals, Inc. announced the advancement of its zelicapavir clinical development program for the treatment of respiratory syncytial virus (RSV), including plans for a registrational Phase 2b/3 clinical trial in high-risk adults and a Phase 2b clinical trial in pediatric patients. Enanta Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing small molecule drugs for infectious diseases.